Autolus Limited Company

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors.
Technology: Cell Therapies
Industry: Personalized Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2014
Employees Number: 11-50
Funding Status: IPO

Visit Website
contact@autolus.com
Register and Claim Ownership